{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:30:17Z","timestamp":1773246617216,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.mbs.2018.05.012","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:29:13Z","timestamp":1526992153000},"page":"67-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV\/HBV coinfection"],"prefix":"10.1016","volume":"302","author":[{"given":"Hasifa","family":"Nampala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livingstone S.","family":"Luboobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Y.T.","family":"Mugisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celestino","family":"Obua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matylda","family":"Jablonska-Sabuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.mbs.2018.05.012_bib0001","first-page":"1707","article-title":"Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV\/HBV coinfected individuals.","volume":"23","author":"Matthews","year":"2009","journal-title":"NIH Public Access"},{"key":"10.1016\/j.mbs.2018.05.012_bib0002","unstructured":"AIDS Info, AIDS info, Side Effects of HIV Medicines: Health information for patients; US department of health and human services (2005) https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/fact-sheets\/22\/63\/hiv-medicines-and-side-effects (Last reviewed 2017)."},{"key":"10.1016\/j.mbs.2018.05.012_bib0003","unstructured":"WHO, WHO, Management of hepatitis b and HIV coinfection, Clinical Protocol for the WHO European Region 7 (2011). http:\/\/www.euro.who.int\/_data\/assets\/pdf_file\/0011\/152012\/e95792.pdf."},{"issue":"19","key":"10.1016\/j.mbs.2018.05.012_bib0004","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMp1201796","article-title":"HIV-HBV Coinfection - a global challenge","volume":"366","author":"Kourtis","year":"2012","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.mbs.2018.05.012_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1086\/525532","article-title":"Hepatitis b virus and HIV coinfection in low-income countries: unmet needs","volume":"46","author":"Puoti","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.mbs.2018.05.012_bib0006","first-page":"367","article-title":"Viral dynamics of hepatitis b virus (HBV) DNA in HIV-1-HBV coinfected individuals: similar effectiveness of lamivudine, tenofovir or combination therapy","volume":"46","author":"Lewin","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.mbs.2018.05.012_bib0007","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1128\/JVI.02594-09","article-title":"Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis b virus leads to an increase in intracellular hepatitis b surface antigen","volume":"84","author":"Iser","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mbs.2012.12.005","article-title":"Mathematical modeling of liver enzyme elevation in HIV mono-infection.","volume":"242","author":"Nampala","year":"2013","journal-title":"Math. Biosci."},{"key":"10.1016\/j.mbs.2018.05.012_bib0009","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/QAD.0b013e328308937c","article-title":"Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4.","volume":"22","author":"Xiao","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.mbs.2018.05.012_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2893.2008.00970.x","article-title":"HCV\/HIV Co-infection: time to re-evaluate the role of HIV in the liver?","volume":"15","author":"Blackard","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.mbs.2018.05.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/473925","article-title":"HIV Infection and TLR signalling in the liver.","volume":"2012","author":"Crane","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"issue":"1","key":"10.1016\/j.mbs.2018.05.012_bib0012","doi-asserted-by":"crossref","first-page":"e8687","DOI":"10.1371\/journal.pone.0008687","article-title":"The effect of human immunodeficiency virus on hepatitis b virus serologic status in co-infected adults","volume":"5","author":"Landrum","year":"2010","journal-title":"PLoS ONE"},{"issue":"18","key":"10.1016\/j.mbs.2018.05.012_bib0013","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/QAD.0b013e3283324344","article-title":"Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immunereconstitution:","volume":"23","author":"Balagopal","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.mbs.2018.05.012_bib0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"Wit","year":"2002","journal-title":"The Journal of Infectious Diseases"},{"issue":"2","key":"10.1016\/j.mbs.2018.05.012_bib0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1086\/381443","article-title":"Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits.","volume":"38","author":"Powderly","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.mbs.2018.05.012_bib0016","unstructured":"C. Liddle, C. Stedman, Hepatic Metabolism of Drugs, Wiley-Blackwell and GastroHep.com, pp. 241\u2013249."},{"key":"10.1016\/j.mbs.2018.05.012_bib0017","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis b virus infection.","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mbs.2018.05.012_bib0018","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/03602530601093489","article-title":"Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.","volume":"39","author":"Hewitt","year":"2007","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.mbs.2018.05.012_bib0019","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1152\/physrev.00061.2009","article-title":"Hepatocyte death: a clear and present danger.","volume":"90","author":"Malhi","year":"2010","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.mbs.2018.05.012_bib0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/00029890.1998.12004907","article-title":"Descartes\u2019s rule of signs revisited.","volume":"105","author":"Anderson","year":"1998","journal-title":"Am. Math. Mon."},{"key":"10.1016\/j.mbs.2018.05.012_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10273660008833041","article-title":"Immune responses and viral phenotype: do replication rate and cytopathogenicity influence virus load?","volume":"2","author":"Wodarz","year":"1999","journal-title":"J. Theor. Med."},{"issue":"5258","key":"10.1016\/j.mbs.2018.05.012_bib0022","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.272.5258.74","article-title":"Population dynamics of immune responses to persistent viruses.","volume":"272","author":"Nowak","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.mbs.2018.05.012_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","article-title":"Dynamics of HIV infections of CD4\u202ft cells.","volume":"114","author":"Perelson","year":"1993","journal-title":"Math. Biosci."},{"issue":"2","key":"10.1016\/j.mbs.2018.05.012_bib0024","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/1027366021000003289","article-title":"A new mathematical model for assessing therapeutic strategies for HIV infection","volume":"4","author":"Gumel","year":"2002","journal-title":"J. Theor. Med."},{"issue":"2","key":"10.1016\/j.mbs.2018.05.012_bib0025","first-page":"43","article-title":"Modelling effective antiretroviral therapy that inhibits HIV production in the liver","volume":"7","author":"Nampala","year":"2015","journal-title":"Antivir. Antiretrovir."},{"key":"10.1016\/j.mbs.2018.05.012_sbref0023","series-title":"Proceedings of the IEEE Sixth International Conference on Systems Biology","first-page":"97","article-title":"Analysis of HBV infection models with ALT.","author":"Su","year":"2012"},{"key":"10.1016\/j.mbs.2018.05.012_bib0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jtbi.2007.02.017","article-title":"Modeling the mechanisms of acute hepatitis b virus infection.","volume":"247","author":"Ciupe","year":"2007","journal-title":"J. Theor. Biol."},{"issue":"47","key":"10.1016\/j.mbs.2018.05.012_bib0028","first-page":"2327","article-title":"Hepatitis b virus infection model with logistic hepatocyte growth and cure rate.","volume":"5","author":"Hattaf","year":"2011","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/135965350601100201","article-title":"A multiphase model of the dynamics of HBV infection in HBeag-negative patients during pegylated interferon-\u03b12a, lamivudine and combination therapy.","volume":"11","author":"Colombatto","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.mbs.2018.05.012_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/743690","article-title":"Mathematical modeling of cytotoxic Lympocyte-mediated immune response to hepatitis b virus infection","volume":"2008","author":"Long","year":"2008","journal-title":"J. Biomed. Biotechnol."},{"issue":"4","key":"10.1016\/j.mbs.2018.05.012_bib0031","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00285-009-0278-3","article-title":"Rich dynamics of a hepatitis b viral infection model with logistic hepatocyte growth.","volume":"60","author":"Hews","year":"2010","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0032","series-title":"Proceedings of the Tenth African Conference on Research in Computer Science and Applied Mathematics","first-page":"109","article-title":"Modelling and analysis of hepatitis b and HIV co-infections.","author":"Bowong","year":"2010"},{"key":"10.1016\/j.mbs.2018.05.012_bib0033","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first european consensus conference on the treatment of chronic hepatitis b and c in HIV co-infected patients.","volume":"42","author":"Alberti","year":"2005","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.mbs.2018.05.012_bib0034","first-page":"20","article-title":"Virology and clinical management of hepatitis b and HIV coinfection.","volume":"11","author":"Fix","year":"2007","journal-title":"PRN Noteb."},{"issue":"3","key":"10.1016\/j.mbs.2018.05.012_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4254\/wjh.v4.i3.91","article-title":"Human immunodeficiency virus infection and the liver.","volume":"4","author":"Crane","year":"2012","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0036","first-page":"778","article-title":"HIV-1 Infection of human macrophages directly induces viperin which inhibits viral production.","volume":"120","author":"Nasr","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.mbs.2018.05.012_bib0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1006\/jtbi.1996.0307","article-title":"Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.","volume":"184","author":"Nowak","year":"1996","journal-title":"J. Theor. Biol."},{"issue":"2","key":"10.1016\/j.mbs.2018.05.012_bib0038","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.nonrwa.2008.10.037","article-title":"Modeling the dynamics of HIV and CD4+ t cells during primary infection.","volume":"11","author":"Srivastava","year":"2008","journal-title":"Nonlinear Anal. Real World Appl."},{"key":"10.1016\/j.mbs.2018.05.012_bib0039","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.mbs.2008.02.001","article-title":"Predicting the potential impact of a cytotoxic t-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?","volume":"212","author":"Smith","year":"2008","journal-title":"Math. Biosci."},{"key":"10.1016\/j.mbs.2018.05.012_bib0040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jtbi.2007.04.014","article-title":"Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.","volume":"247","author":"Rong","year":"2007","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0041","first-page":"1347","article-title":"HIV-1 Dynamics revisited: biphasic decay by cytotoxic t-lymphocyte killing?","volume":"267","author":"Arnaout","year":"2000","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.mbs.2018.05.012_bib0042","first-page":"1","article-title":"Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues.","volume":"6","author":"de Boer","year":"2010","journal-title":"Comput. Biol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0043","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-5564(02)00108-6","article-title":"Reproduction numbers and sub-threshold endemic equilbria for compartmental models of disease transmission.","volume":"180","author":"van den Driessche","year":"2002","journal-title":"Math. Biosci."},{"key":"10.1016\/j.mbs.2018.05.012_bib0044","unstructured":"C. Castillo-Chavez, Z. Feng, W. Huang, On the computation of r0 and its role on global stability 47(2002). https:\/\/www.researchgate.net\/profile\/Carlos_Castillo-Chavez2\/publication\/228915276_ON_THE_COMPUTATION_OF_R_AND_ITS_ROLE_ON_GLOBAL_STABILITY\/links\/0fcfd50a569d32c708000000\/ON-THE-COMPUTATION-OF-R-AND-ITS-ROLE-ON-GLOBAL-STABILITY.pdf."},{"key":"10.1016\/j.mbs.2018.05.012_bib0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s11538-008-9299-0","article-title":"Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model.","volume":"70","author":"Chitnis","year":"2008","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.mbs.2018.05.012_bib0046","series-title":"Sensitivity Analysis of the Basic Reproduction Number and Other Quantities for Infectious Disease Models.","author":"Mikucki","year":"2012"},{"key":"10.1016\/j.mbs.2018.05.012_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/659675","article-title":"Modelling hepatotoxicity of antiretroviral therapy in the liver during HIV monoinfection","author":"Nampala","year":"2014","journal-title":"Int. J. Comput. Math."},{"key":"10.1016\/j.mbs.2018.05.012_bib0048","unstructured":"HIV\/AIDS, Drugs.com, https:\/\/www.drugs.com\/health-guide\/hiv-aids.html, accessed on 03\/06\/2013."},{"key":"10.1016\/j.mbs.2018.05.012_bib0049","unstructured":"Lamivudine PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/098\/original\/HIV_FactSheet_3TC_2016_Mar.pdf accessed on 09\/04\/2014."},{"key":"10.1016\/j.mbs.2018.05.012_bib0050","unstructured":"Emtricitabine PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/102\/original\/HIV_FactSheet_FTC_2016_Mar.pdf, accessed on 02\/04\/2013."},{"key":"10.1016\/j.mbs.2018.05.012_bib0051","unstructured":"Tenofovir PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/101\/original\/HIV_FactSheet_TDF_2016_Mar.pdf?, accessed on 02\/04\/2013."},{"key":"10.1016\/j.mbs.2018.05.012_bib0052","unstructured":"Efavirenz PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/078\/original\/HIV_FactSheet_EFV_2016_Mar.pdf, accessed on 21\/03\/2013."},{"key":"10.1016\/j.mbs.2018.05.012_bib0053","unstructured":"Nevirapine PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/079\/original\/HIV_FactSheet_NVP_2016_Mar.pdf, accessed on 09\/04\/2013."},{"key":"10.1016\/j.mbs.2018.05.012_bib0054","unstructured":"Atazanavir PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/087\/original\/HIV_FactSheet_ATV_2016_Mar.pdf, accessed on 21\/03\/2013."},{"key":"10.1016\/j.mbs.2018.05.012_bib0055","unstructured":"Lopinavir PK Fact Sheet, University of Liverpool, https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/fact_sheets\/pdfs\/000\/000\/083\/original\/HIV_FactSheet_LPV_2016_Mar.pdf, accessed on 02\/04\/2014."},{"issue":"7","key":"10.1016\/j.mbs.2018.05.012_bib0056","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Supplementary information: dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.","volume":"14","author":"Shen","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.mbs.2018.05.012_bib0057","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(01)00190-5","article-title":"Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication","volume":"53","author":"Bisset","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.mbs.2018.05.012_bib0058","unstructured":"CDER, Guidance for industry, estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. department of health and human services food and drug administration center for drug evaluation and research (2005) https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm078932.pdf."},{"key":"10.1016\/j.mbs.2018.05.012_bib0059","unstructured":"AIDSinfo, AIDSinfo drug database (2014) Efavirenz \/ Emtricitabine \/ Tenofovir Disoproxil Fumarate - Full prescribing information http:\/\/aidsinfo.nih.gov\/drugs\/424\/atripla\/0\/professional."},{"key":"10.1016\/j.mbs.2018.05.012_bib0060","unstructured":"The electronic medicine compendium (eMC), https:\/\/www.medicines.org.uk\/emc\/, accessed in April 2014."},{"issue":"1","key":"10.1016\/j.mbs.2018.05.012_bib0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7150\/ijms.1.21","article-title":"Study of the early steps of the hepatitis b virus life cycle.","volume":"1","author":"Lu","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.mbs.2018.05.012_bib0066","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/AAC.46.6.1640-1646.2002","article-title":"Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.","author":"King","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.mbs.2018.05.012_bib0067","doi-asserted-by":"crossref","first-page":"e1001290","DOI":"10.1371\/journal.pmed.1001290","article-title":"Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings","volume":"9","author":"Campbell","year":"2012","journal-title":"PLOS Med."},{"issue":"3","key":"10.1016\/j.mbs.2018.05.012_bib0068","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.","volume":"52","author":"Nunez","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2018.05.012_bib0069","unstructured":"AIDSinfo, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf(2013)."}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002555641730408X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002555641730408X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T20:44:27Z","timestamp":1661287467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002555641730408X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":65,"alternative-id":["S002555641730408X"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2018.05.012","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV\/HBV coinfection","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2018.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}